These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 37996934)

  • 1. Is it possible to extend the dose interval of canakinumab treatment in children with familial Mediterranean fever? PeRA group experience.
    Kavrul Kayaalp G; Çağlayan Ş; Demirkan FG; Guliyeva V; Otar Yener G; Öztürk K; Demir F; Özdel S; Çakan M; Sönmez HE; Sözeri B; Aktay Ayaz N
    Pediatr Rheumatol Online J; 2023 Nov; 21(1):140. PubMed ID: 37996934
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful management of colchicine resistant familial Mediterranean fever patients with a standardized canakinumab treatment protocol: a case series and literature review.
    Eren Akarcan S; Dogantan S; Edeer Karaca N; Aksu G; Kutukculer N
    Rheumatol Int; 2020 Jan; 40(1):161-168. PubMed ID: 31273456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-life data on tapering or discontinuation of canakinumab therapy in patients with familial Mediterranean fever.
    Karabulut Y; Gezer HH; Öz N; Esen İ; Duruöz MT
    Rheumatol Int; 2022 Dec; 42(12):2211-2219. PubMed ID: 36048189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interventions for reducing inflammation in familial Mediterranean fever.
    Yin X; Tian F; Wu B; Xu T
    Cochrane Database Syst Rev; 2022 Mar; 3(3):CD010893. PubMed ID: 35349164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Canakinumab is effective in patients with familial Mediterranean fever resistant and intolerant to the colchicine and/or anakinra treatment.
    Karabulut Y; Gezer HH; Duruöz MT
    Rheumatol Int; 2022 Jan; 42(1):81-86. PubMed ID: 34550430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interventions for reducing inflammation in familial Mediterranean fever.
    Wu B; Xu T; Li Y; Yin X
    Cochrane Database Syst Rev; 2018 Oct; 10(10):CD010893. PubMed ID: 30338514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An "On Demand" canakinumab regimen for treating children with Colchicine-Resistant familial Mediterranean fever - A multicentre study.
    Shehadeh K; Levinsky Y; Kagan S; Zuabi T; Tal R; Aviran NH; Butbul Aviel Y; Tirosh I; Spielman S; Miller-Barmak A; Semo Oz R; Harel L; Chodick G; Amarilyo G
    Int Immunopharmacol; 2024 May; 132():111967. PubMed ID: 38569431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of Canakinumab in Colchicine- and Anakinra-Resistant or -Intolerant Adult Familial Mediterranean Fever Patients: A Single-Center Real-Life Study.
    Babaoglu H; Varan O; Kucuk H; Atas N; Satis H; Salman R; Ozturk MA; Goker B; Tufan A; Haznedaroglu S
    J Clin Rheumatol; 2020 Jan; 26(1):7-13. PubMed ID: 30048391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes.
    De Benedetti F; Gattorno M; Anton J; Ben-Chetrit E; Frenkel J; Hoffman HM; Koné-Paut I; Lachmann HJ; Ozen S; Simon A; Zeft A; Calvo Penades I; Moutschen M; Quartier P; Kasapcopur O; Shcherbina A; Hofer M; Hashkes PJ; Van der Hilst J; Hara R; Bujan-Rivas S; Constantin T; Gul A; Livneh A; Brogan P; Cattalini M; Obici L; Lheritier K; Speziale A; Junge G
    N Engl J Med; 2018 May; 378(20):1908-1919. PubMed ID: 29768139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Total Hip Joint Replacement in a Patient with Colchicine-Resistant Familial Mediterranean Fever under Canakinumab Treatment.
    Matsumoto H; Ohashi H; Fujita Y; Yoshida S; Yokose K; Temmoku J; Matsuoka N; Shinden Y; Kusano K; Sonobe T; Nakamoto Y; Yashiro-Furuya M; Asano T; Sato S; Suzuki E; Yago T; Watanabe H; Migita K
    Tohoku J Exp Med; 2022 Feb; 256(2):169-174. PubMed ID: 35236806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of colchicine-resistant Familial Mediterranean fever in children and adolescents.
    Eroglu FK; Beşbaş N; Topaloglu R; Ozen S
    Rheumatol Int; 2015 Oct; 35(10):1733-7. PubMed ID: 26001859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Canakinumab in colchicine resistant familial Mediterranean fever and other pediatric rheumatic diseases.
    Çakan M; Karadağ ŞG; Ayaz NA
    Turk J Pediatr; 2020; 62(2):167-174. PubMed ID: 32419407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of canakinumab for colchicine-resistant or colchicine-intolerant familial Mediterranean fever: A single-centre observational study.
    Tomokawa T; Koga T; Endo Y; Michitsuji T; Kawakami A
    Mod Rheumatol; 2022 Jul; 32(4):797-802. PubMed ID: 34897516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of anti-interleukin-1 treatment on quality of life in children with colchicine-resistant familial Mediterranean fever: A single-center experience.
    Kurt T; Aydın F; Nilüfer Tekgöz P; Sezer M; Uncu N; Çelikel Acar B
    Int J Rheum Dis; 2020 Jul; 23(7):977-981. PubMed ID: 32558310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Longterm Beneficial Effect of Canakinumab in Colchicine-resistant Familial Mediterranean Fever.
    Laskari K; Boura P; Dalekos GN; Garyfallos A; Karokis D; Pikazis D; Settas L; Skarantavos G; Tsitsami E; Sfikakis PP
    J Rheumatol; 2017 Jan; 44(1):102-109. PubMed ID: 28042127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of canakinumab in adolescents and adults with colchicine-resistant familial Mediterranean fever.
    Gül A; Ozdogan H; Erer B; Ugurlu S; Kasapcopur O; Davis N; Sevgi S
    Arthritis Res Ther; 2015 Sep; 17(1):243. PubMed ID: 26337145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term effectiveness and safety of canakinumab in pediatric familial Mediterranean fever patients.
    Gülez N; Makay B; Sözeri B
    Mod Rheumatol; 2020 Jan; 30(1):166-171. PubMed ID: 30556769
    [No Abstract]   [Full Text] [Related]  

  • 18. Anti-interleukin-1 treatment in 26 patients with refractory familial mediterranean fever.
    Kucuksahin O; Yildizgoren MT; Ilgen U; Ates A; Kinikli G; Turgay M; Erten S
    Mod Rheumatol; 2017 Mar; 27(2):350-355. PubMed ID: 27328763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The feasibility of withdrawing canakinumab in paediatric colchicine-resistant familial Mediterranean fever patients.
    Sözeri B; Sönmez HE; Karadağ ŞG; Bağlan E; Öztürk K; Çakan M; Demir F; Otar Yener G; Özdel S; Aktay Ayaz N
    Clin Exp Rheumatol; 2021; 39 Suppl 132(5):118-123. PubMed ID: 34369353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of effectiveness of anakinra and canakinumab in patients with colchicine-resistant/unresponsive familial Mediterranean fever.
    Şahin A; Derin ME; Albayrak F; Karakaş B; Karagöz Y
    Adv Rheumatol; 2020 Jan; 60(1):12. PubMed ID: 32000860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.